{"count": 48, "results": [{"_id": "39840695", "pmid": 39840695, "title": "Metformin use and pancreatic ductal adenocarcinoma outcomes: a narrative review.", "journal": "ANZ J Surg", "authors": ["Lee D", "Liew MS", "Fourlanos S", "Choi J"], "date": "2025-01-22T00:00:00Z", "doi": "10.1111/ans.19405", "meta_date_publication": "2025 Jan 22", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50274.375, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ use and @<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@pancreatic ductal adenocarcinoma@@@ outcomes: a narrative review.", "citations": {"NLM": "Lee D, Liew MS, Fourlanos S, Choi J. Metformin use and pancreatic ductal adenocarcinoma outcomes: a narrative review. ANZ J Surg. 2025 Jan 22;():. PMID: 39840695", "BibTeX": "@article{39840695, title={Metformin use and pancreatic ductal adenocarcinoma outcomes: a narrative review.}, author={Lee D and Liew MS and Fourlanos S and Choi J}, journal={ANZ J Surg}}"}}, {"_id": "32367394", "pmid": 32367394, "title": "Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus.", "journal": "Langenbecks Arch Surg", "authors": ["Terasaki F", "Sugiura T", "Okamura Y", "Ito T", "Yamamoto Y", "Ashida R", "Ohgi K", "Uesaka K"], "date": "2020-05-01T00:00:00Z", "doi": "10.1007/s00423-020-01874-3", "meta_date_publication": "2020 May", "meta_volume": "405", "meta_issue": "3", "meta_pages": "313-324", "score": 50263.926, "text_hl": "This study aimed to identify prognostic factors for @<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@pancreatic ductal adenocarcinoma@@@ (@<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@PDAC@@@) and determine the utility of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ administration. ", "citations": {"NLM": "Terasaki F, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Ohgi K, Uesaka K. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus. Langenbecks Arch Surg. 2020 May;405(3):313-324. PMID: 32367394", "BibTeX": "@article{32367394, title={Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus.}, author={Terasaki F and Sugiura T and Okamura Y and Ito T and Yamamoto Y and Ashida R and Ohgi K and Uesaka K}, journal={Langenbecks Arch Surg}, volume={405}, number={3}, pages={313-324}}"}}, {"_id": "37293149", "pmid": 37293149, "title": "Anti-cancer effects of metformin in a 3D co-culture model of pancreatic ductal adenocarcinoma.", "journal": "Am J Cancer Res", "authors": ["Hahn S", "Oh BJ", "Kim H", "Han IW", "Shin SH", "Kim G", "Jin SM", "Kim JH"], "date": "2023-05-15T00:00:00Z", "meta_date_publication": "2023", "meta_volume": "13", "meta_issue": "5", "meta_pages": "1806-1825", "score": 50263.926, "text_hl": "Anti-@DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancer@@@ effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in a 3D co-culture model of @<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@pancreatic ductal adenocarcinoma@@@.", "citations": {"NLM": "Hahn S, Oh BJ, Kim H, Han IW, Shin SH, Kim G, Jin SM, Kim JH. Anti-cancer effects of metformin in a 3D co-culture model of pancreatic ductal adenocarcinoma. Am J Cancer Res. 2023;13(5):1806-1825. PMID: 37293149", "BibTeX": "@article{37293149, title={Anti-cancer effects of metformin in a 3D co-culture model of pancreatic ductal adenocarcinoma.}, author={Hahn S and Oh BJ and Kim H and Han IW and Shin SH and Kim G and Jin SM and Kim JH}, journal={Am J Cancer Res}, volume={13}, number={5}, pages={1806-1825}}"}}, {"_id": "32829010", "pmid": 32829010, "title": "Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma.", "journal": "Cancer Lett", "authors": ["Liu SH", "Yu J", "Creeden JF", "Sutton JM", "Markowiak S", "Sanchez R", "Nemunaitis J", "Kalinoski A", "Zhang JT", "Damoiseaux R", "Erhardt P", "Brunicardi FC"], "date": "2020-10-28T00:00:00Z", "doi": "10.1016/j.canlet.2020.08.002", "meta_date_publication": "2020 Oct 28", "meta_volume": "491", "meta_issue": "", "meta_pages": "97-107", "score": 50261.938, "text_hl": "Repurposing @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, @CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@ and @CHEMICAL_Digoxin @CHEMICAL_MESH:D004077 @@@digoxin@@@ as a combination for targeted therapy for @<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@pancreatic ductal adenocarcinoma@@@.", "citations": {"NLM": "Liu SH, Yu J, Creeden JF, Sutton JM, Markowiak S, Sanchez R, Nemunaitis J, Kalinoski A, Zhang JT, Damoiseaux R, Erhardt P, Brunicardi FC. Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma. Cancer Lett. 2020 Oct 28;491():97-107. PMID: 32829010", "BibTeX": "@article{32829010, title={Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma.}, author={Liu SH and Yu J and Creeden JF and Sutton JM and Markowiak S and Sanchez R and Nemunaitis J and Kalinoski A and Zhang JT and Damoiseaux R and Erhardt P and Brunicardi FC}, journal={Cancer Lett}, volume={491}, pages={97-107}}"}}, {"_id": "31892563", "pmid": 31892563, "title": "Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells.", "journal": "Anticancer Res", "authors": ["Wendt EHU", "Schoenrogge M", "Vollmar B", "Zechner D"], "date": "2020-01-01T00:00:00Z", "doi": "10.21873/anticanres.13936", "meta_date_publication": "2020 Jan", "meta_volume": "40", "meta_issue": "1", "meta_pages": "153-160", "score": 50260.902, "text_hl": "CONCLUSION: @CHEMICAL_galloflavin @CHEMICAL_MESH:C572336 @@@Galloflavin@@@, especially in combination with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, has a strong anti-cancerous effect on @<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@pancreatic ductal adenocarcinoma@@@ cells.", "citations": {"NLM": "Wendt EHU, Schoenrogge M, Vollmar B, Zechner D. Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. Anticancer Res. 2020 Jan;40(1):153-160. PMID: 31892563", "BibTeX": "@article{31892563, title={Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells.}, author={Wendt EHU and Schoenrogge M and Vollmar B and Zechner D}, journal={Anticancer Res}, volume={40}, number={1}, pages={153-160}}"}}, {"_id": "32737864", "pmid": 32737864, "pmcid": "PMC7862466", "title": "Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation", "journal": "Protein Cell", "authors": ["Wang C", "Zhang T", "Liao Q", "Dai M", "Guo J", "Yang X", "Tan W", "Lin D", "Wu C", "Zhao Y"], "date": "2021-02-01T00:00:00Z", "doi": "10.1007/s13238-020-00760-4", "meta_date_publication": "2021 Feb", "meta_volume": "12", "meta_issue": "2", "meta_pages": "128-144", "score": 50260.676, "text_hl": "(E) @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ treatment significantly reduced @<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@PDAC metastases@@@ in the liver compared with vehicle control. ", "citations": {"NLM": "Wang C, Zhang T, Liao Q, Dai M, Guo J, Yang X, Tan W, Lin D, Wu C, Zhao Y. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation Protein Cell. 2021 Feb;12(2):128-144. PMID: 32737864", "BibTeX": "@article{32737864, title={Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation}, author={Wang C and Zhang T and Liao Q and Dai M and Guo J and Yang X and Tan W and Lin D and Wu C and Zhao Y}, journal={Protein Cell}, volume={12}, number={2}, pages={128-144}}"}}, {"_id": "32580502", "pmid": 32580502, "pmcid": "PMC7356590", "title": "Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma", "journal": "J Clin Med", "authors": ["Yoo D", "Kim N", "Hwang DW", "Song KB", "Lee JH", "Lee W", "Kwon J", "Park Y", "Hong S", "Lee JW", "Hwang K", "Shin D", "Tak E", "Kim SC"], "date": "2020-06-22T00:00:00Z", "doi": "10.3390/jcm9061953", "meta_date_publication": "2020 Jun 22", "meta_volume": "9", "meta_issue": "6", "meta_pages": "", "score": 50258.926, "text_hl": "In addition, conventional Cox analysis cannot be used to compare survival benefit based on the duration of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment. Based on the comprehensive review of the studies on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@pancreatic ductal adenocarcinoma@@@ (@<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@PDAC@@@), we performed analyses using Cox models with time-varying covariates that incorporate both the start and stop dates of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use.", "citations": {"NLM": "Yoo D, Kim N, Hwang DW, Song KB, Lee JH, Lee W, Kwon J, Park Y, Hong S, Lee JW, Hwang K, Shin D, Tak E, Kim SC. Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma J Clin Med. 2020 Jun 22;9(6):. PMID: 32580502", "BibTeX": "@article{32580502, title={Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma}, author={Yoo D and Kim N and Hwang DW and Song KB and Lee JH and Lee W and Kwon J and Park Y and Hong S and Lee JW and Hwang K and Shin D and Tak E and Kim SC}, journal={J Clin Med}, volume={9}, number={6}}"}}, {"_id": "33042621", "pmid": 33042621, "title": "Metformin activates the STING/IRF3/IFN-beta pathway by inhibiting AKT phosphorylation in pancreatic cancer.", "journal": "Am J Cancer Res", "authors": ["Ren D", "Qin G", "Zhao J", "Sun Y", "Zhang B", "Li D", "Wang B", "Jin X", "Wu H"], "date": "2020-09-01T00:00:00Z", "meta_date_publication": "2020", "meta_volume": "10", "meta_issue": "9", "meta_pages": "2851-2864", "score": 50258.84, "text_hl": "However, the mechanisms underlying the antitumor effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@PDAC@@@ remain unclear. ", "citations": {"NLM": "Ren D, Qin G, Zhao J, Sun Y, Zhang B, Li D, Wang B, Jin X, Wu H. Metformin activates the STING/IRF3/IFN-beta pathway by inhibiting AKT phosphorylation in pancreatic cancer. Am J Cancer Res. 2020;10(9):2851-2864. PMID: 33042621", "BibTeX": "@article{33042621, title={Metformin activates the STING/IRF3/IFN-beta pathway by inhibiting AKT phosphorylation in pancreatic cancer.}, author={Ren D and Qin G and Zhao J and Sun Y and Zhang B and Li D and Wang B and Jin X and Wu H}, journal={Am J Cancer Res}, volume={10}, number={9}, pages={2851-2864}}"}}, {"_id": "32157435", "pmid": 32157435, "title": "An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases.", "journal": "J Cancer Res Clin Oncol", "authors": ["Broadhurst PJ", "Hart AR"], "date": "2020-05-01T00:00:00Z", "doi": "10.1007/s00432-020-03177-y", "meta_date_publication": "2020 May", "meta_volume": "146", "meta_issue": "5", "meta_pages": "1369-1375", "score": 50258.695, "text_hl": "However, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may only be efficacious in @SPECIES_9606 @@@patients@@@ with inoperable @<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@pancreatic ductal adenocarcinoma@@@ (@<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@PDAC@@@) without @DISEASE_Neoplasm_Metastasis @DISEASE_MESH:D009362 @@@liver metastases@@@. ", "citations": {"NLM": "Broadhurst PJ, Hart AR. An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases. J Cancer Res Clin Oncol. 2020 May;146(5):1369-1375. PMID: 32157435", "BibTeX": "@article{32157435, title={An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases.}, author={Broadhurst PJ and Hart AR}, journal={J Cancer Res Clin Oncol}, volume={146}, number={5}, pages={1369-1375}}"}}, {"_id": "31685560", "pmid": 31685560, "title": "Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.", "journal": "Cancer Epidemiol Biomarkers Prev", "authors": ["Toriola AT", "Luo S", "Thomas TS", "Drake BF", "Chang SH", "Sanfilippo KM", "Carson KR"], "date": "2020-01-01T00:00:00Z", "doi": "10.1158/1055-9965.EPI-19-0781", "meta_date_publication": "2020 Jan", "meta_volume": "29", "meta_issue": "1", "meta_pages": "169-175", "score": 50258.637, "text_hl": "BACKGROUND: The effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use on survival among @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@pancreatic ductal adenocarcinoma@@@ (@<m>DISEASE_Carcinoma_Pancreatic_Ductal</m> @DISEASE_MESH:D021441 @@@PDAC@@@) is controversial. ", "citations": {"NLM": "Toriola AT, Luo S, Thomas TS, Drake BF, Chang SH, Sanfilippo KM, Carson KR. Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus. Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):169-175. PMID: 31685560", "BibTeX": "@article{31685560, title={Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.}, author={Toriola AT and Luo S and Thomas TS and Drake BF and Chang SH and Sanfilippo KM and Carson KR}, journal={Cancer Epidemiol Biomarkers Prev}, volume={29}, number={1}, pages={169-175}}"}}]}